NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

Cardiff Oncology, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCRDF
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CRDF COVERAGE

What’s moving Cardiff Oncology, Inc. now

Current reporting with the operating signal separated from the noise.

01
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

Investors are testing whether Cardiff Oncology, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

The story matters when it changes Cardiff Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CRDF filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-11 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-14 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-09-14 · Period 2026-09-14SEC ↗8-KMaterial company eventFiled 2026-08-11 · Period 2026-08-11SEC ↗8-KMaterial company eventFiled 2026-07-16 · Period 2026-07-14SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-08-26 · Period 2026-08-26SEC ↗DEFA14AOfficial SEC filingFiled 2026-08-26SEC ↗
EARNINGS / QUARTERLY TRACKER

Cardiff Oncology, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.